Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation
- 1 November 2000
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 26 (9) , 1005-1009
- https://doi.org/10.1038/sj.bmt.1702648
Abstract
Thrombotic thrombocytopenic purpura (TTP) has emerged as one of the main transplant-related complications over the last 15 years. The current study defines the incidence and the risk factors for the occurrence of TTP in 131 consecutive leukemic children who were transplanted between January 1994 and December 1997 at four Italian pediatric centers. Patients with ALL (101), AML (21), MDS (9), underwent an HLA-identical sibling BMT (82) or an HLA-identical unrelated BMT (49), receiving a conditioning regimen consisting of high-dose chemotherapy in 24 patients and of F-TBI combined with high-dose chemotherapy in 107 patients. The diagnosis of TTP was retrospectively evaluated on the basis of parallel criteria. TTP treatment varied according to the protocol of each treatment center. Twenty-eight of 131 patients (21.4%) developed TTP at a median of 46 days (range 21–80) after BMT. Multivariate analysis demonstrated that the risk of TTP was higher in patients who underwent unrelated BMT (P value = 0.02). Acute GVHD, stage of disease at BMT, conditioning with TBI, gender, age, did not appear to be associated with the occurrence of TTP. As to the outcome, TTP resolved in 19 patients while in nine it was the principal cause of death (32.1%). In patients with TTP, LDH peak value was the only statistically significant factor (P = 0.001) related to severe TTP. In conclusion, our experience demonstrates that leukemic children undergoing BMT, especially from an unrelated donor, should be carefully assessed for TTP which appears to be a severe and relatively common transplant-related complication when strict diagnostic criteria are applied. Bone Marrow Transplantation (2000) 26, 1005–1009.Keywords
This publication has 21 references indexed in Scilit:
- Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantationBone Marrow Transplantation, 1999
- Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignanciesBone Marrow Transplantation, 1998
- Hemolytic uremic syndrome after allogeneic or autologous hematopoietic stem cell transplantation for childhood malignanciesBone Marrow Transplantation, 1998
- Management of thrombotic microangiopathy following allogeneic transplantation: what is the role of plasma exchange?Bone Marrow Transplantation, 1997
- Treatment of thrombotic thrombocytopenic purpura with defibrotidAmerican Journal of Hematology, 1993
- Plasma cytokine levels in thrombotic thrombocytopenic purpuraAmerican Journal of Hematology, 1992
- Inhibition of Tissue Plasminogen Activator Inhibitor by Defibrotide in Atherosclerotic PatientsSeminars in Thrombosis and Hemostasis, 1989
- Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromesBritish Journal of Haematology, 1983
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976